Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

NEW YORK – Biodesix said today that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.

Under the agreement, the companies will use Biodesix's Diagnostic Cortex biomarker discovery platform to analyze the circulating proteome of advanced pancreatic cancer patients treated with Immodulon's candidate immunotherapy IMM-101.

"From this collaboration and by utilizing the Biodesix Diagnostic Cortex in identifying blood-based proteomic biomarkers, we hope to facilitate selection of those patients most likely to respond to IMM-101. This could improve the efficiency of treatment and patient care, and accelerate our clinical trial programs," Jaap Kampinga, Immodulon's CEO, said in a statement.

"Our proprietary Diagnostic Cortex machine learning-based biomarker discovery platform is well suited to advancing the clinical research for IMM-101," said Biodesix CEO David Brunel. "This research collaboration with Immodulon builds on our track record of developing companion diagnostics to optimize treatments with the potential to deliver much needed therapies to critically ill patients."

Financial and other terms of the agreement were not disclosed.